Heatwurx (NASDAQ:PCSA) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Heatwurx (NASDAQ:PCSA) posted its earnings results on Thursday. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01, FiscalAI reports.

Heatwurx Stock Performance

Shares of PCSA stock traded down $0.01 on Friday, hitting $0.31. 2,096,921 shares of the company’s stock traded hands, compared to its average volume of 9,369,590. The stock has a market capitalization of $15.40 million, a price-to-earnings ratio of -0.13 and a beta of 1.45. The company’s fifty day simple moving average is $0.27 and its 200 day simple moving average is $0.25. Heatwurx has a one year low of $0.15 and a one year high of $1.50.

Analysts Set New Price Targets

Several analysts have weighed in on PCSA shares. Zacks Research downgraded Heatwurx from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 26th. HC Wainwright decreased their price objective on shares of Heatwurx from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, September 2nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Heatwurx in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Heatwurx presently has an average rating of “Hold” and an average price target of $1.00.

About Heatwurx

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells.